ALS

Alesco

Short interest: 0.00%; −0.29 pp 30d; as of 15 Jan 2013
Reported shorts: 3
Shares on issue: 94.193M

Alesco (ALS) News

Latest articles and price-sensitive announcements with AI sentiment classification.

Kalkine

Neutral

14 Sept

Macquarie Group Limited Ends Status as Substantial Holder in ALS Limited as of September 2026

ALS Limited (ASX:ALQ) announced that Macquarie Group Limited along with its controlled bodies corporate has ceased to be a substantial holder in the company, effective 9 September 2026, as disclosed in a Form 605 filing submitted to the company. Key Highlights Macquarie Group Limited and its controlled entities ceased substantial holding in ALS Limited on 9 September 2026. The prior substantial holding notice was submitted on 10 September 2026, dated 7 September 2026. Simone Kovacic, Company ...

Stockhead

Neutral

9 Sept

Key US health body funds expanded access initiative for ALS patients

Neurizon said the EAP was expected to provide up to 200 people living with ALS access to NUZ-001 for up ... Read More The post Key US health body funds expanded access initiative for ALS patients appeared first on Stockhead.

Google News

Neutral

6 Sept

ALS Ltd Subject to BlackRock Group Initial Substantial Holder Notice With 5.03% Voting Power - Kalkine

ALS Ltd Subject to BlackRock Group Initial Substantial Holder Notice With 5.03% Voting Power  Kalkine

Stockhead

Neutral

4 Aug

Neurizon reports Q4 milestones across pivotal ALS program and capital strategy

Neurizon said the June quarter was marked by rapid progress in Regimen I of its amyotrophic lateral sclerosis (ALS) platform ... Read More The post Neurizon reports Q4 milestones across pivotal ALS program and capital strategy appeared first on Stockhead.

Stockhead

Neutral

3 Aug

Long Shortz with Neurizon Therapeutics: Milestones stack up for ALS program

Neurizon has completed enrolment in the ALS Platform Trial while securing new non-dilutive funding to support its clinical program. ... Read More The post Long Shortz with Neurizon Therapeutics: Milestones stack up for ALS program appeared first on Stockhead.

Motley Fool

Positive

27 July

ALS FY26 results: Record growth, leadership moves, digital push

ALS posts record FY26 results with standout Minerals growth and advances in digital transformation. The post ALS FY26 results: Record growth, leadership moves, digital push appeared first on The Motley Fool Australia.

Google News

Neutral

26 July

ALS Shares Make Green-to-Red YTD Move: What Comes Next? - thebull.com.au

ALS Shares Make Green-to-Red YTD Move: What Comes Next?  thebull.com.au

Stockhead

Neutral

17 July

Neurizon completes enrolment in pivotal ALS trial, topline results brought forward

The final participant has completed their baseline visit and started treatment, completing enrolment into Regimen I. ... Read More The post Neurizon completes enrolment in pivotal ALS trial, topline results brought forward appeared first on Stockhead.

Kalkine

Positive

18 June

Neurizon’s ALS Milestone: Why This Small-Cap Biotech Is Gaining Attention

Highlights Neurizon Therapeutics has crossed a significant clinical milestone in its ALS development program. Recruitment and dosing progress continue to exceed expectations within the HEALEY ALS Platform Trial. The update places renewed attention on one of the more closely watched names in the Australian biotech sector. Neurizon Therapeutics has crossed the halfway dosing mark in its ALS trial program, highlighting continued clinical momentum and strong recruitment progress. Clinical milesto...

Stockhead

Neutral

12 June

Neurizon ALS platform trial passes 50pc dosing milestone ahead of schedule

Neurizon has dosed 129 of 240 participants in Regimen I of the HEALEY ALS platform trial evaluating NUZ-001, with recruitment ... Read More The post Neurizon ALS platform trial passes 50pc dosing milestone ahead of schedule appeared first on Stockhead.

Kalkine

Positive

12 June

Why Is ALS Under Pressure Despite Strong Results and an ASX 50 Upgrade?

Highlights ALS shares declined ahead of the stock trading ex-dividend despite reporting a strong annual performance. The laboratory testing specialist is set to join the S&P/ASX 50 later this month. Investors continue focusing on dividend payments, index inclusion, and growth across commodities and life sciences testing. ALS remains under the spotlight as investors assess dividend payments, ASX 50 inclusion, and ongoing growth across commodities and life sciences testing operations. Austr...

Kalkine

Positive

8 June

ALS Dividend Countdown Begins as Ex-Dividend Date Nears

Highlights ALS is approaching its ex-dividend date, putting renewed attention on its shareholder distribution profile. Earnings growth and dividend growth have remained supportive themes for the company in recent years. Dividend sustainability remains a key focus as payout levels continue to balance shareholder returns and business investment. ALS remains on dividend watchlists as its ex-dividend date approaches, supported by earnings growth, cash generation and diversified global operations....

Kalkine

Positive

7 June

ALS Dividend Countdown Begins: What Shareholders Should Know

Highlights ALS is approaching its upcoming ex-dividend date, making timing an important consideration for eligible shareholders. The company continues to demonstrate earnings growth alongside a long history of dividend increases. Dividend sustainability remains a key area of focus as payout levels continue to represent a significant portion of earnings. ALS is approaching its ex-dividend date with market attention focused on dividend sustainability, earnings growth and the company's diversifi...

Google News

Positive

7 June

ALS Limited (ASX:ALQ) Stock Goes Ex-Dividend In Just Four Days - simplywall.st

ALS Limited (ASX:ALQ) Stock Goes Ex-Dividend In Just Four Days  simplywall.st

Stockhead

Neutral

27 May

Neurizon ALS trial expands cohort to 240 patients as enrolment accelerates

Regimen I of Neurizon Therapeutics’ ALS Platform Trial will increase its total patient cohort by 50% to 240 participants. ... Read More The post Neurizon ALS trial expands cohort to 240 patients as enrolment accelerates appeared first on Stockhead.

Google News

Neutral

27 May

How Investors Are Reacting To ALS (ASX:ALQ) Earnings And Its Strict 15% ROCE Deal Filter - simplywall.st

How Investors Are Reacting To ALS (ASX:ALQ) Earnings And Its Strict 15% ROCE Deal Filter  simplywall.st

Google News

Positive

22 May

Assessing ALS (ASX:ALQ) Valuation After Strong Full Year Earnings And EPS Growth - simplywall.st

Assessing ALS (ASX:ALQ) Valuation After Strong Full Year Earnings And EPS Growth  simplywall.st

Google News

Neutral

19 May

ALS (ASX:ALQ) Margin Improvement Challenges Bearish Narratives In FY 2026 Results - simplywall.st

ALS (ASX:ALQ) Margin Improvement Challenges Bearish Narratives In FY 2026 Results  simplywall.st

Google News

Positive

18 May

ALS Limited (ASX:ALQ) Falls Despite Record FY26 Profit: Buy the Dip or Wait? - Stocks Down Under

ALS Limited (ASX:ALQ) Falls Despite Record FY26 Profit: Buy the Dip or Wait?  Stocks Down Under

Kalkine

Neutral

18 May

Why Is ALS Drawing Fresh Attention Across Commodities?

Highlights Commodities-linked laboratory services remain central to mining operations. Resource activity continues shaping demand across testing and inspection sectors. Global industrial supply chains remain closely connected to commodities services. Australia’s commodities services sector continues attracting attention as mining infrastructure, laboratory testing, and industrial monitoring systems remain closely tied to global resource activity. Australia’s industrial and c...

Motley Fool

Positive

17 May

ALS reports record FY26 earnings and dividend uplift

ALS Ltd reported 10.7% revenue growth, a 25.8% rise in NPAT, stronger margins, and a higher dividend. The post ALS reports record FY26 earnings and dividend uplift appeared first on The Motley Fool Australia.

Google News

Neutral

14 May

Assessing ALS (ASX:ALQ) Valuation After May 2026 Cyber Security Incident - simplywall.st

Assessing ALS (ASX:ALQ) Valuation After May 2026 Cyber Security Incident  simplywall.st

Kalkine

Neutral

13 May

Breakthrough ALS Study Pushes Neurizon Into Spotlight

Highlights New oral liquid ALS study cleared for Australian trial Liquid formulation aims to support treatment continuity Clinical development program continues to expand Neurizon Therapeutics is advancing its ALS drug development program after securing ethics approval for a new oral liquid study in Australia, supporting broader clinical progress and patient-focused treatment accessibility. Neurizon Advances ALS Research With New Clinical Milestone Australian biotech company Neurizon Th...

Kalkine

Neutral

9 Apr

ALS Limited Sector Strength And Position Across All Ordinaries

Highlights Strong upward movement observed across recent trading phases Elevated valuation multiples compared with broader sector peers Expansion momentum supported by laboratory testing demand across industries The industrial testing and inspection services sector plays a critical role in supporting environmental monitoring, mining services, food quality assurance, and life sciences.  ALS Ltd, (ASX:ALQ), is a global testing and inspection services company that provides analytical, certi...

Stockhead

Neutral

7 Apr

Long Shortz with Neurizon Therapeutics: NUZ-001 builds momentum in ALS trial with new data

New preclinical data shows NUZ-001 increases activity of multiple protein clearance pathways in neuronal models. ... Read More The post Long Shortz with Neurizon Therapeutics: NUZ-001 builds momentum in ALS trial with new data appeared first on Stockhead.

Kalkine

Neutral

9 Mar

ALS and Qantas Insights Reflect Movements Across ASX 200

Highlights Qantas (QAN), Brambles (BXB), and ALS (ALQ) show varying performance in the ASX 200 index. Industrial and transport sectors are active amid mixed market signals across ASX stock market. Key companies continue to influence investor attention within ASX mining stocks and broader ASX dividend stocks. Qantas, Brambles, and ALS impact industrial, transport, and inspection sectors, shaping activity across ASX 200, ASX 100, and broader ASX market trends. The ASX 200 index continues ...